for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GW Pharmaceuticals PLC- ADR

GWPRF.PK

Latest Trade

11.16USD

Change

-0.34(-2.96%)

Volume

3,801

Today's Range

10.55

 - 

11.16

52 Week Range

4.48

 - 

12.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

GW Pharmaceuticals Plc Reports Third Quarter 2020 Financial Results

Nov 3 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.Q3 REVENUE $137.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $132.1 MILLION.QTRLY LOSS PER SHARE $0.03.

GW Pharmaceuticals receives Australian TGA approval for Epidyolex (Cannabidiol)

Sept 23 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::GW PHARMACEUTICALS - RECEIVES AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA) APPROVAL FOR EPIDYOLEX® (CANNABIDIOL).GW PHARMACEUTICALS - EPIDYOLEX IS FOR TREATMENT OF SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF CHILDHOOD-ONSET EPILEPSY.

GW Pharmaceuticals PLC Reports Second Quarter 2020 Financial Results And Operational Progress

Aug 6 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.Q2 REVENUE $121.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $119.7 MILLION.QTRLY LOSS PER SHARE $0.02.

FDA Approves Epidiolex Oral Solution To Treat Seizures Associated With Tuberous Sclerosis Complex

Aug 3 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::FDA APPROVES EPIDIOLEX® (CANNABIDIOL) ORAL SOLUTION TO TREAT SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX.GW PHARMACEUTICALS PLC - AGE-RANGE FOR ALL EPIDIOLEX INDICATIONS EXPANDED TO INCLUDE PATIENTS ONE YEAR OF AGE AND OLDER.

GW Pharmaceuticals Reports Quarterly Loss Per Share $0.02

May 11 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.Q1 REVENUE $120.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $108.4 MILLION.QUARTERLY LOSS PER SHARE $0.02.

GW Pharmaceuticals PLC And Its U.S. Subsidiary Greenwich Biosciences Announce That Epidiolex (Cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

April 6 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::GW PHARMACEUTICALS PLC AND ITS U.S. SUBSIDIARY GREENWICH BIOSCIENCES, INC. ANNOUNCE THAT EPIDIOLEX® (CANNABIDIOL) ORAL SOLUTION HAS BEEN DESCHEDULED AND IS NO LONGER A CONTROLLED SUBSTANCE.GW PHARMACEUTICALS PLC - RECEIVED NOTIFICATION FROM UNITED STATES DEA CONFIRMING THAT EPIDIOLEX IS NO LONGER SUBJECT TO CONTROLLED SUBSTANCES ACT.GW PHARMACEUTICALS PLC - FILED A POST-APPROVAL SUPPLEMENT WITH FDA TO REMOVE SCHEDULE V DESIGNATION FROM EPIDIOLEX.

GW Pharmaceuticals And Greenwich Biosciences Submit Supplemental New Drug Application To FDA For Epidiolex

Feb 3 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::GW PHARMACEUTICALS AND GREENWICH BIOSCIENCES SUBMIT SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA FOR EPIDIOLEX® (CANNABIDIOL) FOR THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX.

GW Pharmaceuticals Says Two Of Co's Medicines Recommended By UK's NICE To Receive Routine Reimbursement From NHS England

Nov 10 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::GW PHARMACEUTICALS PLC - TWO OF CO'S MEDICINES, EPIDYOLEX AND SATIVEX, RECOMMENDED BY UK'S NICE TO RECEIVE ROUTINE REIMBURSEMENT FROM NHS ENGLAND.

GW Pharmaceuticals PLC Reports Q3 Loss Per Share Of $0.04

Nov 5 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::REPORTS FINANCIAL RESULTS AND OPERATIONAL PROGRESS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019.REVENUE FOR QUARTER ENDED SEPTEMBER 30, 2019 WAS $91.0 MILLION COMPARED TO $2.4 MILLION.CASH AND CASH EQUIVALENTS AT SEPTEMBER 30, 2019 WERE $554.7 MILLION COMPARED TO $591.5 MILLION AS OF DECEMBER 31, 2018.QTRLY LOSS PER SHARE $0.04.Q3 REVENUE VIEW $85.3 MILLION -- REFINITIV IBES DATA.

GW Pharmaceuticals PLC Reports Q2 Financial Results

Aug 6 (Reuters) - GW Pharmaceuticals PLC <GWPH.O>::REPORTS FINANCIAL RESULTS AND OPERATIONAL PROGRESS FOR THE SECOND QUARTER ENDED JUNE 30, 2019.Q2 REVENUE $72 MILLION VERSUS $3.3 MILLION.Q2 REVENUE ESTIMATE $56 MILLION -- REFINITIV IBES DATA.EPIDIOLEX U.S. Q2 NET SALES OF $68.4 MILLION.QTRLY EARNINGS PER SHARE $0.21.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up